Exicure, Inc. Form 8-K Summary
Business Context and Reporting Period
Exicure, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on August 22, 2018. The filing primarily addresses the completion of a private placement financing and the entry into material definitive agreements with accredited investors.
Key Financial Metrics
- Gross Proceeds: Approximately $22 million raised from the sale of 4,889,217 shares of common stock at $4.50 per share.
- Placement Fees: $1,680,104 paid in cash to placement agents (Ladenburg Thalmann, Castle Hill Capital Partners, and Katalyst Securities LLC).
- Reimbursed Expenses: Up to $87,480 reimbursed to placement agents.
- Outstanding Shares: 44,344,038 shares of Common Stock issued and outstanding following the transaction.
- Liquidity: The filing does not provide specific cash balance figures, only projections regarding sufficiency.
Material Changes
The primary material change is the increase in equity capital and share count resulting from the private placement. The company issued nearly 4.9 million new shares, increasing the total outstanding share count to approximately 44.3 million. This transaction was conducted on a "reasonable best efforts" basis and exempt from registration under Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D.
Outlook, Management Commentary, and Risks
Liquidity Outlook: Management stated that existing cash and cash equivalents, bolstered by the financing, are sufficient to meet anticipated cash requirements into 2020.
Registration Rights: The company entered into a Registration Rights Agreement requiring the filing of a "resale" registration statement with the SEC within 30 calendar days of the final closing.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual expenditures and cash runway may vary significantly based on the progress of pre-clinical and clinical trials, the need for additional trials, potential collaborations, and unforeseen cash needs.
Investor Verification Checklist
- Verify the final closing date and total number of shares sold to confirm the exact outstanding share count.
- Review the filed "resale" registration statement (expected within 30 days of final closing) to confirm the ability of investors to sell shares publicly.
- Monitor subsequent filings for updates on clinical trial progress and actual cash burn rates versus the projected runway into 2020.
- Confirm the identity of the accredited investors and any potential conflicts of interest with the placement agents.